Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
Authors
Keywords
-
Journal
EUROPEAN HEART JOURNAL
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2021-04-11
DOI
10.1093/eurheartj/ehab225
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Polypill with or without Aspirin in Persons without Cardiovascular Disease
- (2020) Salim Yusuf et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
- (2019) Gholamreza Roshandel et al. LANCET
- A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial
- (2019) Jon-David Schwalm et al. LANCET
- Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?
- (2018) Kamlesh Khunti et al. DIABETES OBESITY & METABOLISM
- 2018 ESC/ESH Guidelines for the management of arterial hypertension
- (2018) Bryan Williams et al. EUROPEAN HEART JOURNAL
- Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial
- (2018) Ajay Gupta et al. LANCET
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
- (2018) Scott M. Grundy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cumulative in-trial and post-trial effects of blood pressure and lipid lowering
- (2017) Yoichiro Hirakawa et al. JOURNAL OF HYPERTENSION
- Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
- (2016) Eva Lonn et al. CANADIAN JOURNAL OF CARDIOLOGY
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients
- (2016) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
- (2016) Dena Ettehad et al. LANCET
- Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease
- (2016) Eva M. Lonn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
- (2016) Salim Yusuf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Statin effects on atherosclerotic plaques: regression or healing?
- (2015) Marcio Sommer Bittencourt et al. BMC Medicine
- Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies
- (2015) Maciej Banach et al. BMC Medicine
- Long-term efficacy and safety of statin treatment beyond six years: A meta-analysis of randomized controlled trials with extended follow-up
- (2014) Han-lu Lv et al. PHARMACOLOGICAL RESEARCH
- Long-Term Follow-Up of Moderately Hypercholesterolemic Hypertensive Patients Following Randomization to Pravastatin vs Usual Care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
- (2013) Karen L. Margolis et al. Journal of Clinical Hypertension
- An Overview of the Extra-Lipid Effects of Rosuvastatin
- (2008) Michael S. Kostapanos et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started